Skip to main content

Table 1 Demographic data and the levels of total and oligomeric α-synuclein and the oligomer/t-α-synuclein ratio in the CSF

From: Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

 

Controls

PDD

DLB

AD

Number

98

30

71

48

Male/Female

35/63

22/8 a

49/22 a

13/35 c, d

Age, years

69 (11.6)

76 (5.5)a

74 (7.4)b

77 (5.6)a, e

MMSE

29 (28–30)

23.5 (17–25)a

21 (17–24.75)a

21 (19–23)a

α-Synuclein oligomers

37,882 (21,763–136,685)

73,309 (36,361–326,297) b

40,440 (22,235–137,845)

26,441 (21,548–44,332) b, c, e

α-Synuclein oligomers/α-Synuclein total

549 (372–2149)

1,333 (492–5,973) b

811 (379–2,238)

333 (199–718) a, c, d

α-Synuclein total

67.00 (52.00–86.00)

61.50 (51.25–68.25)

58.00 (43.75–75.00)

94.00 (76.00–121.00) a, c, d

  1. The data are presented as the median (25th to 75th percentile), except for age, where the data were normally distributed. The data for age are presented as the mean (SD). The α-synuclein oligomer levels are presented in RLU. The total α-synuclein levels are presented in ng/L. For α-synuclein total and α-synuclein oligomers/α-synuclein total, only CSF samples with hemoglobin less than 1,000 ng/L were included.
  2. a,bCompared with the controls, aP < 0.001, bP < 0.05.
  3. cCompared with PDD patients, cP < 0.001.
  4. d, eCompared with DLB patients, dP < 0.001, eP < 0.05.